Role and targetability of RNA-binding proteins in prostate cancer drug resistance
Description of the granted funding
Cancer poses an increasing global burden. While advancements with better treatment options have increased patient survival times, formation of tumor resistance to currently available drugs is a prevailing challenge with many cancers. To overcome treatment resistance, therapies need to be designed to target the drug resistance mechanisms. Against prostate cancer, current drugs are initially effective. However, cancer cells often find a way to tolerate these drugs and form a resistance. In this project, we study how much does regulation of RNA molecules, the expression products of genes, provide the required flexibility for cancer cells to dodge the bullets during drug treatments. Especially, role of RNA-binding proteins in these processes is studied. The results of this research will help understand molecular mechanisms of cancer drug resistance and provide targets to design novel therapeutics against.
Show moreStarting year
2023
End year
2027
Granted funding
Funder
Research Council of Finland
Funding instrument
Academy projects
Other information
Funding decision number
357490
Fields of science
Biomedicine
Research fields
Biolääketieteet
Identified topics
cancer